IBRX·Nasdaq·US
ImmunityBio
ImmunityBio is a clinical-stage biotechnology company developing and commercializing immunotherapies for cancer and infectious diseases. Its lead commercial product is ANKTIVA, and its portfolio also includes cell therapy, vaccine, and other immune-modulating programs.
Recent Activity
Updated Oct 3, 2026
–ImmunityBio's founder met with Turkish President, a meeting reported to fuel hopes of company expansion.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.